Crossref
What are the benefits and harms of erythropoiesis-stimulating agents (ESAs) (erythropoietin or darbepoetin alfa) for preterm or low-birthweight infants?
Cochrane Clinical Answers · 15.07.2026
DOI: 10.1002/cca.4827 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cochrane Clinical Answers, online erschienen am 15.07.2026. Verfasst von Adarsh Gupta. Die Arbeit nennt 18 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Gupta, A. (2026). What are the benefits and harms of erythropoiesis-stimulating agents (ESAs) (erythropoietin or darbepoetin alfa) for preterm or low-birthweight infants?. Cochrane Clinical Answers. https://doi.org/10.1002/cca.4827
Vancouver
Gupta A. What are the benefits and harms of erythropoiesis-stimulating agents (ESAs) (erythropoietin or darbepoetin alfa) for preterm or low-birthweight infants?. Cochrane Clinical Answers. 2026. doi:10.1002/cca.4827
BibTeX
@article{Gupta2026,
author = {Gupta, Adarsh},
title = {What are the benefits and harms of erythropoiesis-stimulating agents (ESAs) (erythropoietin or darbepoetin alfa) for preterm or low-birthweight infants?},
journal = {Cochrane Clinical Answers},
year = {2026},
doi = {10.1002/cca.4827}
}
EUVIMED